Open Bypass Surgery
ProcedureOpen Bypass Surgery with Autogenous vein or PTFE Graft
NCT Number: NCT01602159
This is a prospective randomized controlled trial to compare clinical improvement, cost effectiveness and patency rates between new and improved Nitinol stents and open bypass surgery in the superficial femoral artery disease.
Secondary outcomes also include comparing quality of life, re-intervention rate, mortality, morbidity and time to return to work or regular activities.
Patients with superficial femoral artery lesions will be considered. Patients with TASC II A lesions will not be randomized but treated with PTA/stenting as standard of care. Patients with TASC II B and C lesions will be prospectively randomized into either receiving open bypass or stenting.
Patients with TASC D lesions will be treated with open bypass surgery after angiography.
The investigators will collect pre-procedure, peri-procedural and clinical follow-up data on all enrolled the patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinical Inclusion:
Anatomical Inclusion:
Exclusion criteria
Clinical exclusion:
Anatomic Exclusion:
Open Bypass Surgery with Autogenous vein or PTFE Graft
Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
Other names: Life Stent flexStar Stent System by Bard Inc. Tempe AZ
Time frame: 12 Month Post Operatively
Clinical Improvement is measured as at least 1 Rutherford category
Time frame: 12 Month Post Operatively
Primary, primary assisted and secondary at 6, 12 month
Time frame: 12 Month Post Operatively
Cost Effectiveness factoring procedure and hospital admission costs
Time frame: 12 Month Post Operatively
Improvement of quality of life measured using VQL
Time frame: 12 Month Post Operatively
Time frame: 12 Month Post Operatively
Time frame: 12 Month Post Operatively
Time frame: 12 Month Post Operatively
Time frame: 12 Month Post Operatively
Johns Hopkins University
Other
Acronym: ROBUST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04434586
Cardiovascular Diseases, Claudication
Lille, France
View Trial DetailsNCT06416644
Arterial Occlusive Diseases, Arteriosclerosis
Faro, Algarve, Portugal
View Trial DetailsNCT05291247
Arterial Occlusive Diseases, Arteriosclerosis
Baden-Baden, Baden-Wurttemberg, Germany
View Trial DetailsNCT05451485
Arterial Occlusive Diseases, Brain Diseases
Arnhem, Gelderland, Netherlands
View Trial Details